Accuracy of18F-FDG PET/CT in Detecting Pelvic and Paraaortic Lymph Node Metastasis in Patients with Endometrial Cancer

2008 ◽  
Vol 190 (6) ◽  
pp. 1652-1658 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Koji Murakami ◽  
Erena Yamasaki ◽  
Ichio Fukasawa ◽  
Noriyuki Inaba ◽  
...  
Author(s):  
Mustafa Taş ◽  
Adem Yavuz ◽  
Mehmet Dolanbay ◽  
Eser Kaya ◽  
Gökalp Öner ◽  
...  

Surgery Today ◽  
2015 ◽  
Vol 45 (4) ◽  
pp. 478-478
Author(s):  
Ryuichi Karashima ◽  
Masayuki Watanabe ◽  
Yu Imamura ◽  
Satoshi Ida ◽  
Yoshifumi Baba ◽  
...  

2014 ◽  
Vol 15 (18) ◽  
pp. 7719-7724 ◽  
Author(s):  
Ru Tan ◽  
Shu-Zhan Yao ◽  
Zhao-Qin Huang ◽  
Jun Li ◽  
Xin Li ◽  
...  

2019 ◽  
Vol 44 (3) ◽  
pp. 828-835 ◽  
Author(s):  
Thitinan Chulroek ◽  
Hamed Kordbacheh ◽  
Dearada Wangcharoenrung ◽  
Kamonwon Cattapan ◽  
Pedram Heidari ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Luca Foppiani ◽  
Simona Sola ◽  
Manlio Cabria ◽  
Gianluca Bottoni ◽  
Arnoldo Piccardo

Over 50% of patients with papillary thyroid carcinoma (PTC) have cervical lymph-node metastasis on diagnosis, and up to 30% show nodal recurrence after surgery plus radioactive iodine (131I) (RAI) therapy. The combination of ultrasonography (US) and fine-needle aspiration cytology (FNAC) and the measurement of thyroglobulin (Tg) in washout fluid are cornerstones in the diagnosis of nodal metastasis. In the absence of anti-Tg antibodies, unstimulated serum thyroglobulin (Tg) levels are generally a reliable marker of recurrent disease, and 18F-FDG positron emission tomography (PET)/computed tomography (CT) plays an important role in the imaging work-up. We report the case of a 65-year-old man evaluated for a large multinodular goitre which caused compressive symptoms; the dominant nodule in the left lobe presented suspicious features on US. Thyroid function showed subclinical hypothyroidism, calcitonin was normal, serum thyroglobulin levels were low, and anti-thyroid antibodies were absent. The prevalent left nodule showed an intense uptake on 18F-FDG PET/CT but proved benign at FNAC. On the basis of the suspicious clinical and imaging features, total thyroidectomy was performed. Histology revealed a tall-cell variant of PTC with scattered expression of Tg and diffuse high expression of cytokeratin (CK) 19; RAI therapy was performed. Within 6 years of surgery, left laterocervical lymph-node recurrence was twice detected (first at levels II and III, then at levels IV and VI) by US and 18F-FDG-PET/CT and was confirmed by FNAC. Tg levels in the washout fluid proved clearly diagnostic of metastasis only in the second, larger, recurrence, whereas serum Tg levels (in the absence of anti-Tg antibodies) always remained undetectable on L-thyroxine therapy. Surgery was performed on both recurrences, and histology confirmed lymph-node metastasis of PTC. Immunohistochemical expression of Tg and CK 19 was similar to that of the primary tumour. No further relapses have occurred to date. Posttherapy (surgery and RAI) unstimulated serum Tg levels may not be a reliable marker of nodal recurrence in patients with differentiated thyroid cancer (DTC) that produces low amounts of Tg.


Author(s):  
Hui-Hua Chen ◽  
Wan-Hua Ting ◽  
Hsu-Dong Sun ◽  
Ming-Chow Wei ◽  
Ho-Hsiung Lin ◽  
...  

Background: to elucidate the predictors of progression-free survival (PFS) and overall survival (OS) in high-risk endometrial cancer patients. Methods: the medical records of all consecutivewomen with high-risk endometrial cancer were reviewed. Results: among 92 high-risk endometrial cancer patients, 30 women experienced recurrence, and 21 women died. The 5-year PFS and OS probabilities were 65.3% and 75.9%, respectively. Multivariable Cox regression revealed that body mass index (hazard ratio (HR) = 1.11), paraaortic lymph node metastasis (HR = 11.11), lymphovascular space invasion (HR = 5.61), and sandwich chemoradiotherapy (HR = 0.15) were independently predictors of PFS. Body mass index (HR = 1.31), paraaortic lymph node metastasis (HR = 32.74), non-endometrioid cell type (HR = 11.31), and sandwich chemoradiotherapy (HR = 0.07) were independently predictors of OS. Among 51 women who underwent sandwich (n = 35) or concurrent (n = 16) chemoradiotherapy, the use of sandwich chemoradiotherapy were associated with better PFS (adjusted HR = 0.26, 95% CI = 0.08–0.87, p = 0.03) and OS (adjusted HR = 0.11, 95% CI = 0.02–0.71, p = 0.02) compared with concurrent chemoradiotherapy. Conclusion: compared with concurrent chemoradiotherapy, sandwich chemoradiotherapy was associated with better PFS and OS in high-risk endometrial cancer patients. In addition, high body mass index, paraaortic lymph node metastasis, and non-endometrioid cell type were also predictors of poor OS in high-risk endometrial cancer patients.


2014 ◽  
Vol 12 (1) ◽  
pp. 309 ◽  
Author(s):  
Takaaki Fujii ◽  
Reina Yajima ◽  
Hiroki Morita ◽  
Satoru Yamaguchi ◽  
Soichi Tsutsumi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document